Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 7/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.48 |
| ▸ | HTR3B | O95264 | 3/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17255017 | 0.96 | HRH4 (0.44) | HTR3AHRH4HTR3EHTR3BHTR3D | |
| SCHEMBL23160983 | 0.85 | HRH4 (0.51) | HTR3AHRH4HTR3EHTR3BHTR3D | |
| SCHEMBL20078423 | 0.83 | HTR3A (0.50) | HTR3AHRH4HTR3EHTR3BHTR3D | |
| SCHEMBL20057376 | 0.83 | HTR3A (0.53) | HTR3AHRH4HTR3EHTR3BHTR3D | |
| SCHEMBL18057404 | 0.83 | PDE10A (0.39) | HRH4KDM4EALDH1A1HRH3 | |
| SCHEMBL18057398 | 0.82 | PDE10A (0.37) | KDM4EALDH1A1CYP1A2KMT2A | |
| SCHEMBL19365030 | 0.82 | SMN1; SMN2 (0.41) | KDM4EALDH1A1KMT2A | |
| SCHEMBL18057400 | 0.81 | MAP4K4 (0.39) | HRH4 | |
| SCHEMBL18057407 | 0.81 | PDE10A (0.42) | HRH4HRH3 | |
| SCHEMBL18042578 | 0.79 | KDM4E (0.49) | HTR3AHRH4HTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361937-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2020-11-19 | — | — | US | disclosed |
| US-10745403-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2020-08-18 | — | — | US | disclosed |
| US-10590134-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10442801-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180079750-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2018-03-22 | — | — | US | disclosed |
| EP-3219716-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | Pimera, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9758518-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758518-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9512123-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512123-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160326176-A1 | Novel Compositions, Uses and Methods for Making Them | PIMERA, INC | 2016-11-10 | — | — | US | disclosed |
| US-20160326176-A1 | Novel Compositions, Uses and Methods for Making Them | PIMERA, INC | 2016-11-10 | — | — | US | disclosed |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2016-09-08 | — | — | US | disclosed |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326176-A1 | Novel Compositions, Uses and Methods for Making Them | BAX, CASP3, BCL2 | HTR3A 4237/4885HRH4 4546/4885HTR3E 2808/4885 |
| US-10590134-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | HTR3A 4002/4885HRH4 4586/4885HTR3E 2458/4885 |
| US-20180079750-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | HTR3A 4237/4885HRH4 4546/4885HTR3E 2808/4885 |
| US-10745403-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | HTR3A 4002/4885HRH4 4586/4885HTR3E 2458/4885 |
| US-20200361937-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | HTR3A 4237/4885HRH4 4546/4885HTR3E 2808/4885 |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | HTR3A 4237/4885HRH4 4546/4885HTR3E 2808/4885 |
| US-10442801-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | HTR3A 4002/4885HRH4 4586/4885HTR3E 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.